Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeted Therapy in Melanoma and Mechanisms of Resistance
Anna M. Czarnecka, Ewa Bartnik, Michał Fiedorowicz, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 13, pp. 4576-4576
Open Access | Times Cited: 143

Showing 1-25 of 143 citing articles:

Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma
Amod A. Sarnaik, Omid Hamid, Nikhil I. Khushalani, et al.
Journal of Clinical Oncology (2021) Vol. 39, Iss. 24, pp. 2656-2666
Open Access | Times Cited: 266
Melanoma Management: From Epidemiology to Treatment and Latest Advances
Joana Lopes, Cecília M. P. Rodrigues, Maria Manuela Gaspar, et al.
Cancers (2022) Vol. 14, Iss. 19, pp. 4652-4652
Open Access | Times Cited: 92
BRAF Mutations in Melanoma: Biological Aspects, Therapeutic Implications, and Circulating Biomarkers
Giorgia Castellani, Mariachiara Buccarelli, Maria Beatrice Arasi, et al.
Cancers (2023) Vol. 15, Iss. 16, pp. 4026-4026
Open Access | Times Cited: 56
Emerging Therapeutic Strategies to Overcome Drug Resistance in Cancer Cells
Pankaj Garg, Jyoti Malhotra, Prakash Kulkarni, et al.
Cancers (2024) Vol. 16, Iss. 13, pp. 2478-2478
Open Access | Times Cited: 32
Macrophage polarization in the tumor microenvironment: Emerging roles and therapeutic potentials
Wenru Zhang, Mengmeng Wang, Chonghao Ji, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 177, pp. 116930-116930
Open Access | Times Cited: 27
Mechanisms of Melanoma Progression and Treatment Resistance: Role of Cancer Stem-like Cells
Youssef Al Hmada, Robert T. Brodell, Naji Kharouf, et al.
Cancers (2024) Vol. 16, Iss. 2, pp. 470-470
Open Access | Times Cited: 15
PTEN Dual Lipid- and Protein-Phosphatase Function in Tumor Progression
Anne Liu, Yan‐Yu Zhu, Weiping Chen, et al.
Cancers (2022) Vol. 14, Iss. 15, pp. 3666-3666
Open Access | Times Cited: 42
BRAF Inhibitor Resistance in Melanoma: Mechanisms and Alternative Therapeutic Strategies
Jingqin Zhong, Wangjun Yan, Chunmeng Wang, et al.
Current Treatment Options in Oncology (2022) Vol. 23, Iss. 11, pp. 1503-1521
Open Access | Times Cited: 41
Melanoma classification and management in the era of molecular medicine
Sarem Rashid, Michael F. Shaughnessy, Hensin Tsao
Dermatologic Clinics (2022) Vol. 41, Iss. 1, pp. 49-63
Closed Access | Times Cited: 39
Exploring the Potent Anticancer Activity of Essential Oils and Their Bioactive Compounds: Mechanisms and Prospects for Future Cancer Therapy
Fatouma Mohamed Abdoul‐Latif, Ayoub Ainane, Ibrahim Houmed Aboubaker, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 8, pp. 1086-1086
Open Access | Times Cited: 39
MAPK Pathway Inhibitors in Thyroid Cancer: Preclinical and Clinical Data
Louis Schubert, Mohamed Lamine Mariko, Jérôme Clerc, et al.
Cancers (2023) Vol. 15, Iss. 3, pp. 710-710
Open Access | Times Cited: 29
Targeting PI3K/AKT/mTOR Signaling to Overcome Drug Resistance in Cancer
Muhammad Tufail, Wendong Wan, Canhua Jiang, et al.
Chemico-Biological Interactions (2024) Vol. 396, pp. 111055-111055
Closed Access | Times Cited: 8
FAK inhibition combined with the RAF-MEK clamp avutometinib overcomes resistance to targeted and immune therapies in BRAF V600E melanoma
Simone Lubrano, Rodolfo Daniel Cervantes‐Villagrana, Farhoud Faraji, et al.
Cancer Cell (2025)
Closed Access | Times Cited: 1
Resistance to Molecularly Targeted Therapies in Melanoma
Meet Patel, Adam Eckburg, Shahina Gantiwala, et al.
Cancers (2021) Vol. 13, Iss. 5, pp. 1115-1115
Open Access | Times Cited: 52
Treatment of Metastatic Melanoma with a Combination of Immunotherapies and Molecularly Targeted Therapies
Taylor Rager, Adam Eckburg, Meet Patel, et al.
Cancers (2022) Vol. 14, Iss. 15, pp. 3779-3779
Open Access | Times Cited: 31
Microbiota, Oxidative Stress, and Skin Cancer: An Unexpected Triangle
Barbara Azzimonti, Chiara Ballacchino, Paola Zanetta, et al.
Antioxidants (2023) Vol. 12, Iss. 3, pp. 546-546
Open Access | Times Cited: 19
PARP1 expression predicts PARP inhibitor sensitivity and correlates with metastatic potential and overall survival in melanoma
Lisa Marie Fröhlich, Ana Villar‐Miyar, Tamara Heintze, et al.
International Journal of Cancer (2024) Vol. 155, Iss. 2, pp. 203-210
Open Access | Times Cited: 6
Curing Stage IV Melanoma: Where Have We Been and Where Are We?
Pui Ying Chan, Pippa Corrie
American Society of Clinical Oncology Educational Book (2024) Vol. 44, Iss. 3
Closed Access | Times Cited: 6
The future of targeted kinase inhibitors in melanoma
Signe Caksa, Usman Baqai, Andrew E. Aplin
Pharmacology & Therapeutics (2022) Vol. 239, pp. 108200-108200
Open Access | Times Cited: 25
A pH/ROS dual-responsive system for effective chemoimmunotherapy against melanoma via remodeling tumor immune microenvironment
Leilei Wang, Shanshan He, Rong Liu, et al.
Acta Pharmaceutica Sinica B (2023) Vol. 14, Iss. 5, pp. 2263-2280
Open Access | Times Cited: 15
More than Just Skin-Deep: A Review of Imaging’s Role in Guiding CAR T-Cell Therapy for Advanced Melanoma
Conor M. Prendergast, Kathleen M. Capaccione, Egesta Lopci, et al.
Diagnostics (2023) Vol. 13, Iss. 5, pp. 992-992
Open Access | Times Cited: 13
Dual targeting of MAPK and PI3K pathways unlocks redifferentiation of Braf-mutated thyroid cancer organoids
Hélène Lasolle, Andréa Alex Schiavo, Adrien Tourneur, et al.
Oncogene (2023) Vol. 43, Iss. 3, pp. 155-170
Open Access | Times Cited: 13
Clonal differences underlie variable responses to sequential and prolonged treatment
Dylan L. Schaff, Aria J. Fasse, Phoebe E. White, et al.
Cell Systems (2024) Vol. 15, Iss. 3, pp. 213-226.e9
Open Access | Times Cited: 5
Diclofenac Enhances the Response of BRAF Inhibitor to Melanoma Through ROS/p38/p53 Signaling
Haihong Qin, Zheng Li, Jinfeng Wu, et al.
Clinical and Experimental Pharmacology and Physiology (2025) Vol. 52, Iss. 3
Closed Access
Novel drugs approved by the EMA, the FDA and the MHRA in 2024: A year in review
Stavros Topouzis, Andreas Papapetropoulos, S P H Alexander, et al.
British Journal of Pharmacology (2025)
Open Access
Page 1 - Next Page

Scroll to top